The key drivers of increased investor interest in AstraZeneca are the strong performance of its oncology and cardiovascular ...
BostonGene has entered a new collaboration with AstraZeneca to apply its foundation AI model to oncology drug development, aiming to improve early trial decision-making around safety, efficacy, and ...
The data presented covered everything from its mainstay acalabrutinib, sold as Calquence, to the eye-catching AZD0120, an ...
US biotech BostonGene has struck a research collaboration with British pharma AstraZeneca (LSE: AZN) to explore the use of ...
JOHANNESBURG, Dec 9 (Reuters) - Efficacy results may not be ready for months from a trial of AstraZeneca and Oxford University's coronavirus vaccine in South Africa, the principal investigator of the ...
U.S. health officials have raised concerns over AstraZeneca’s COVID-19 vaccine trial, accusing the pharmaceutical giant of using outdated and potentially misleading efficacy data. “The DSMB expressed ...
BostonGene, the developer of an AI foundation model for tumor and immune biology, has entered a strategic collaboration with ...
BostonGene, the developer of the leading AI foundation model for tumor and immune biology, today announced a strategic collaboration with AstraZeneca, a global, science-led biopharmaceutical company ...
On Thursday, the Cellular, Tissue, and Gene Therapies Advisory Committee will discuss AstraZeneca Plc’s (NASDAQ:AZN) supplemental biologics license application for Andexxa (coagulation factor Xa ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback